P-524. Immunological Determinants and Clinical Trajectories of Pediatric Varicella-Zoster Virus Reactivation: A Prospective Cohort Analysis

Abstract Background This prospective cohort study elucidates novel pathomechanisms underlying varicella-zoster virus (VZV) reactivation in immunocompetent children, challenging prevailing assumptions about viral latency.Pediatric Herpes ZosterChild with Dermatomal grouped vesicles along left L3 dermatomeTzank SmearTzank Smear showing multinucleated giant cells Methods Through comprehensive immunological profiling of 42 pediatric patients at a tertiary referral center, we identified distinct cytokine signatures (IL-6, IFN-γ elevations >2.5-fold baseline) correlating with dermatomal lesion severity (ρ=0.72, p< 0.001). High-resolution multiplex PCR confirmed VZV clade homology between primary varicella and subsequent reactivation strains in 93% of cases, refuting exogenous reinfection hypotheses.Histopathology of herpes zoster vesicleHistopathology with Hematoxylin and eosin stain showing ballooning degeneration and keratinocytes and intranuclear eosinophilic inclusions with margination of chromatin, resembling Cowdry A type inclusions Results Notably, 31% of subjects exhibited transient CD4+ lymphopenia (mean 412 cells/μL vs. age-matched controls 986 cells/μL, p=0.008) despite normal immunoglobulin profiles, suggesting localized immune dysregulation. Multivariate regression revealed early childhood varicella infection (< 36 months) conferred 3.8-fold increased reactivation risk (95%CI 1.9-7.1, p< 0.005), independent of vaccination status. Advanced neuroimaging demonstrated subclinical dorsal root ganglion inflammation in 22% of asymptomatic dermatomes, implicitating broader neuronal involvement than previously documented. Therapeutic monitoring showed oral valacyclovir (60mg/kg/day) achieved viral clearance 2.3 days faster than historical acyclovir regimens (95%CI 1.1-3.8 days), with complete neuralgia resolution by day 14 in all patients. Longitudinal TCR sequencing revealed persistent VZV-specific memory cell expansion ( >18 months post-reactivation), providing unprecedented insights into pediatric adaptive immunity. These findings necessitate paradigm shifts in managing pediatric zoster, advocating for: 1) universal immune surveillance in reactivation cases, 2) optimized antiviral dosing protocols, and 3) targeted vaccination strategies addressing viral sanctuary sites. Conclusion This research establishes a novel conceptual framework for understanding age-dependent VZV pathogenesis, offering transformative biomarkers for risk stratification and therapeutic monitoring in pediatric infectious diseases. Disclosures All Authors: No reported disclosures